CDRS = Children's Depression Rating Scale, CGI = Clinical Global Impressions, NS = not significant, HAMD = Hamilton Depression Rating Scale. Fluoxetine First line a ≤11 yr, 5 mg/day; ≥12 yr ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

In a post-hoc analysis, cariprazine seemed to be effective in treating both depressive and manic episodes of bipolar I disorder across age groups.

Major strides for the company on two fronts – psychedelic therapies and treatment-resistant depression (TRD) – came in the ...

However, in people with mild cognitive impairment, the presence of depressive symptoms was tied to a lower likelihood of amyloid pathology (OR 0.73, 95% CI 0.61-0.89, P =0.001), Oomens and colleagues ...

DUBLIN - GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company valued at $551.5 million, announced today significant results from its Phase 2b clinical trial for GH001, an ...

PLC reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with ...

The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...